Treatment of Latent Tuberculosis Infection Prevents Active Disease
Yes, treatment of latent tuberculosis infection (LTBI) significantly reduces the risk of developing active tuberculosis disease, with efficacy ranging from 60-90% and protection lasting up to 19 years. 1
Evidence for Prevention of Active TB
The effectiveness of LTBI treatment is well-established across multiple populations:
Overall risk reduction: Treatment with any anti-TB drug reduces active TB incidence by approximately 32% (RR 0.68,95% CI 0.54-0.85) 2
Tuberculin skin test positive individuals: The benefit is most pronounced in those with positive TST, showing a 62% risk reduction (RR 0.38,95% CI 0.25-0.57) 2
Real-world effectiveness: In a Japanese outbreak study, treatment reduced the risk of active TB by 81% compared to no treatment (4.8% vs 25.0% developed active disease) 3
High-risk populations: Among patients on TNF antagonists, LTBI treatment reduced TB incidence from 12.34 to 4.07 per 1,000 person-years (incidence rate ratio 0.33,95% CI 0.17-0.63) 4
Recommended Treatment Regimens
The 2020 CDC/NTCA guidelines 5 prioritize regimens based on efficacy, tolerability, and completion rates:
Preferred Regimens:
- 3 months of weekly isoniazid plus rifapentine (3HP): Strong recommendation with moderate evidence - offers excellent tolerability, shorter duration, and higher completion rates
- 4 months of daily rifampin (4R): Strong recommendation with moderate evidence in HIV-negative individuals
- 3 months of daily isoniazid plus rifampin (3RH): Conditional recommendation
Alternative Regimens:
- 6 months of daily isoniazid (6H): Strong recommendation for those unable to take preferred regimens
- 9 months of daily isoniazid (9H): Conditional recommendation
Population-Specific Considerations
Strongly recommended for systematic testing and treatment 1:
- People living with HIV
- Adult and child contacts of pulmonary TB cases
- Patients initiating anti-TNF treatment
- Patients on dialysis
- Pre-transplant patients (organ or hematological)
- Patients with silicosis
Conditionally recommended (based on TB epidemiology and resources):
- Prisoners
- Healthcare workers
- Immigrants from high TB burden countries
- Homeless persons
- Illicit drug users
Important Caveats
Duration of protection: While highly effective, delayed reactivation can occur. In one study, among treated individuals who developed active TB, the average time to reactivation was 53 months, indicating that protection is not absolute 3
TST status matters: The benefit is substantially greater in TST-positive individuals (62% reduction) compared to TST-negative individuals (11% reduction, RR 0.89, not statistically significant) 2
Mortality benefit: While LTBI treatment reduces active TB incidence, overall all-cause mortality reduction has not been consistently demonstrated (RR 0.94,95% CI 0.85-1.05), though some benefit was seen in TST-positive individuals receiving isoniazid 2
Adverse events: Rifamycin-based combination regimens have higher rates of treatment discontinuation due to adverse events compared to isoniazid monotherapy, though they offer shorter treatment duration and better completion rates 5, 6. Grade 3-4 hepatotoxicity is most common with 9H, followed by 1HP and 6H 6
Drug interactions: Rifamycin-based regimens have significant drug interactions with warfarin, oral contraceptives, azole antifungals, and HIV antiretrovirals - requiring careful consideration in regimen selection 5
Clinical Algorithm
- Identify high-risk individuals requiring systematic LTBI screening
- Test for LTBI using TST or IGRA
- Rule out active TB with chest radiography before initiating treatment
- Select regimen based on:
- Patient preference for shorter vs. longer duration
- Drug interaction profile
- HIV status
- Likelihood of adherence
- Local drug availability
- Prioritize 3HP or 4R for most patients due to superior completion rates and shorter duration 5